Malawian communities cautiously back infection studies with safeguards

Controlled Human Infection Models (CHIM) are research studies in which volunteers are deliberately exposed to pathogens so scientists can better understand how disease develops and choose the most promising treatments and vaccines. These studies are often done with healthy adults, but scientists argue they are most useful when run among people who live where an infection is common and who might benefit from new interventions. The team led by Anthony E. Chirwa wanted to hear directly from communities about whether CHIM should ever include groups besides healthy adults, specifically people living with HIV (PLHIV), and how communities view the idea of a tuberculosis CHIM (TB CHIM). Because TB challenge studies are complex, the researchers also explored views on using Bacillus Calmette Guerin (BCG) as a safer intermediate step toward TB CHIM. The study took place in Malawi and focused on gathering local perspectives before any such trials are planned, recognizing that ethical design requires understanding the hopes, concerns and cultural views of the people who would be affected.

To gather these views the researchers ran fourteen focus group discussions (FGD) and eight in-depth interviews (IDI) with a wide range of stakeholders across Malawi. Participants included past and potential study participants, health workers, community advisory groups, religious leaders and medical opinion leaders. Discussions and interviews were recorded, transcribed and analysed using thematic and framework analysis to find common patterns in what people said. Four main themes emerged. First, there was a general acceptance of CHIM and confidence in the research practice and motivations of investigators. Second, when the examples turned to at-risk populations such as PLHIV and complex pathogens like TB, people voiced clear concerns about safety, the need for proper consent and the importance of community consultation. Third, cultural views surfaced about gender roles, tissue sampling and the idea of participants staying in a residence for research. Fourth, many respondents supported a cautious pathway that starts with a BCG CHIM and works toward a safe TB CHIM, and they suggested safety caveats, regulatory measures and wide public awareness campaigns before moving forward.

The findings suggest practical steps for researchers and regulators who consider CHIM in places where infections are common. First, community engagement matters: listening to health workers, advisory groups, religious leaders and potential participants can surface specific concerns about consent, sampling and the logistics of residential stays that would otherwise be missed. Second, many people in Malawi are open to trials that include PLHIV if clear safety measures, oversight and transparent consent processes are in place. Third, using Bacillus Calmette Guerin (BCG) as an intermediate, lower-risk challenge could be a way to build trust and evidence before attempting full tuberculosis CHIM. Finally, respondents recommended stronger regulations and broad public awareness campaigns so communities understand the science, risks and benefits. Taken together, the study points to a path that balances scientific need with ethical safeguards and local cultural realities before advancing to more complex challenge studies.